GPNMB and metabolic dysfunction-associated steatotic liver disease: Furthermore, we have found the presence of soluble and secreted form of Gpnmb in rodents and human sera and postulated that it is a promising biomarker for NASH and Gpnmb may be a new therapeutic key molecule for NAFLD.